NSEGeneral Updates1d ago · 4 Sept 2026, 03:54 pm
General Updates
Vaishali Pharma Limited · VAISHALI
✦ AI SummaryFundraise
Vaishali Pharma Limited has received listing approval from the National Stock Exchange of India Limited for 45,37,865 equity shares allotted on a preferential basis.
Analysis Scores
Earnings Impact2/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Vaishali Pharma Limited has informed the Exchange about General Updates
Attachments (1)
📄pdf
Download →
VAISHALI_04092026155410_Reg_30_Final.pdf
View document text
Date: 04th September, 2026
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.
Stock Code: VAISHALI
Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015.
Dear Sir/Madam,
Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of
India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing
Regulations"), we wish to inform you that the Company has received the Listing Approval
from the National Stock Exchange of India Limited ("NSE") vide its letter bearing Reference
No. NSE/LIST/56477 dated 03rd September, 2026.
NSE has approved the listing and admission to dealings of 45,37,865 (Forty-Five Lakhs
Thirty-Seven Thousand Eight Hundred Sixty-Five) Equity Shares of face value of Rs. 2/-
each, allotted on a preferential basis, bearing distinctive numbers from 130462131 to
134999995, subject to receipt of confirmation from the depositories, namely National
Securities Depository Limited (NSDL) and Central Depository Services (India) Limited
(CDSL), regarding credit of the said equity shares to the beneficiaries' accounts.
A copy of the Listing Approval Letter received from NSE is enclosed herewith for the
information of the Exchange.
Kindly take the above information on record.
Thanking You,
Yours Faithfully,
For Vaishali Pharma Limited
Vishwa Mekhia
Company Secretary and Compliance Officer
Ref: NSE/LIST/56477 September 03, 2026
The Company Secretary
Vaishali Pharma Limited
Dear Sir/Madam,
Sub: In - Principle approval for listing of 45,37,865 Equity shares of Rs. 2/- each allotted on
preferential basis.
We are in receipt of your application for in-principle approval for listing of 45,37,865 Equity shares of
Rs. 2/- each allotted on preferential basis bearing distinctive numbers from 130462131 to 134999995.
We have perused the listing application and the related documents/details submitted by you for listing of
the above shares.
We are pleased to grant the in-principle approval for listing of the above shares on the Exchange. The said
shares would be listed and admitted to dealings on the Exchange on receipt of the confirmation from the
depositories i.e. NSDL/CDSL for credit of beneficiaries' accounts.
The Exchange reserves its right to withdraw its in-principle approval for listing at a later stage if the
information submitted to the Exchange is found to be incomplete/incorrect/misleading/false or in
contravention of any Rules, Bye-laws and Regulations of the Exchange, SEBI (LODR) Regulations,
2015, Guidelines/ Regulations issued by statutory authorities, etc.
Yours faithfully,
For National Stock Exchange of India Limited
Pooja Pashte
Manager
National Securities Depository Limited
Central Depository Services Limited
P.S. Checklist of all the further issues is available on website of the exchange at the following URL:
https://www.nseindia.com/companies-listing/raising-capital-further-issues-main-sme-checklist
The National Stock Exchange of India (NSE) has announced the launch of NEAPS mobile application.
The app can be downloaded from the App Store/ Play store with the name “NEAPS APP”
This Document is Digitally Signed
Signer: POOJA RISHIKESH PASHTE
Date: Thu, Sep 3, 2026 17:52:36 IST
Location: NSE